White Paper - Why Diagnostic Regulation Matters in Pharmaceutical Development - and Current Best Practices
Born out of a World CDx Summit, Hanson Wade has partnered with key opinion leaders from Johnson & Johnson, Bristol Myers Squibb, Eli Lilly, Merck, Sanofi, Daiichi Sankyo, Regeneron, and others to provide a critical pharma perspective on the evolving regulatory landscape for biomarkers and companion diagnostics.
Download the white paper to gain:
- Key insights into the role of diagnostics in pharmaceutical development and regulatory expectations
- A high-level overview of regulatory environments in the US, EU, Japan, and China
- Best practices for aligning diagnostic and therapeutic development to drive innovation and improve patient access to precision therapies
What’s more, a handful of the leading authors will be joining a panel at the 15th World Clinical Biomarkers & CDx Summit to take an in-depth discussion on some key challenges discussed in this white paper – see the full panel synopsis here.
Explore the New Agenda
Hear the latest imaging, multi-omics, single-cell and functional assays, enhanced by AI-driven digital biomarker strategies, enabling earlier and smarter treatment decisions for oncology, autoimmune, neurological, chronic and rare disease patients
Partner with Us
Position your solutions alongside leading biomarker, diagnostic and technology providers, to ensure your brand is front and center, and retain your place as the partner of choice in the ever-expanding precision medicine space
Join 850+ Specialist Experts
Be part of the liveliest Rx-Dx conversations with like-minded industry peers spanning a range of precision therapy modalities, and build high-value connections during dedicated networking sessions designed to foster collaborations